Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O0dmlEPTB;MD6wNFAxPTF|IN88US=> MWrTRW5ITVJ?
NCI-H1703 NEHZPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\OTWM2OD1yLkCwNFkxOiEQvF2= MXfTRW5ITVJ?
KASUMI-1 NYTPeHljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFOYRxUUN3ME2wMlAxPjh{IN88US=> M2DDbXNCVkeHUh?=
CGTH-W-1 M1i5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnqTWM2OD1yLkCwO|IzKM7:TR?= MYDTRW5ITVJ?
A204 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMEC5PVIh|ryP MUTTRW5ITVJ?
HOP-62 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjW[IEzUUN3ME2wMlExQDN4IN88US=> MmX0V2FPT0WU
H-EMC-SS MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUGwNFUh|ryP M{H6RnNCVkeHUh?=
KU812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37BPGlEPTB;MD6xOlU4PyEQvF2= MkLqV2FPT0WU
EM-2 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrVOW9KSzVyPUCuNVY5OTZizszN NV7lSllkW0GQR1XS
LAMA-84 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTiPW9sUUN3ME2wMlE4PjZ3IN88US=> MXLTRW5ITVJ?
JAR M1fGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLYTWM2OD1yLkKzPVg6KM7:TR?= NUjZTXJ[W0GQR1XS
G-361 NUXYSYJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLaXI5KSzVyPUCuN|I{OjVizszN MmLtV2FPT0WU
KG-1 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln1TWM2OD1yLkO3OlQzKM7:TR?= NXHVXZRIW0GQR1XS
BV-173 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{THN2lEPTB;MD6zPVMzKM7:TR?= NYS1cXRxW0GQR1XS
K5 M2HD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPzTWM2OD1yLkSyNVI4KM7:TR?= M{PPWHNCVkeHUh?=
MEG-01 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\tUINKSzVyPUCuOFI{PjFizszN NEmw[nFUSU6JRWK=
MFM-223 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK0b2pKSzVyPUCuOFQ4PzZizszN M2rrTHNCVkeHUh?=
BE-13 M{DkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrWTWM2OD1yLkWxNFA5KM7:TR?= M36xdXNCVkeHUh?=
NEC8 NYHVcXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTEPVBuUUN3ME2wMlczOTF|IN88US=> NWPWcG43W0GQR1XS
SW756 NGnYR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHZXZVrUUN3ME2wMlk6QDR4IN88US=> NYP5fI9DW0GQR1XS
A2780 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMEGxOFYh|ryP M{XL[HNCVkeHUh?=
NB14 M3ztVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwMEG4NFEh|ryP M1iycXNCVkeHUh?=
H4 NIq5cXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzZWIxKSzVyPUGuNFY1OjJizszN MoPPV2FPT0WU
SK-OV-3 NX;hN5lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2WmlEPTB;MT6wOlY{OyEQvF2= NXLKTWxLW0GQR1XS
AN3-CA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S1RWlEPTB;MT6wPFM5QSEQvF2= MYPTRW5ITVJ?
A427 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\pZ4FHUUN3ME2xMlExOzhzIN88US=> M4HPe3NCVkeHUh?=
ES7 NVLYOmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPKdI5UUUN3ME2xMlEyOzN2IN88US=> M2K5fnNCVkeHUh?=
AGS M2fRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLZTWM2OD1zLkGxN|k2KM7:TR?= Mn;SV2FPT0WU
G-402 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DwVWlEPTB;MT6xOFY6PCEQvF2= NEewRWhUSU6JRWK=
ES5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW5ZVVKSzVyPUGuNVczPDhizszN MnL5V2FPT0WU
DEL NWj1PWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzVTWM2OD1zLkK1OFU4KM7:TR?= NEnqZ|FUSU6JRWK=
NB10 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwM{K1OVch|ryP MnjXV2FPT0WU
NCI-H1581 NV\RZ5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q4cGlEPTB;MT6zPVA1OiEQvF2= NGrX[2ZUSU6JRWK=
D-566MG NH3Fd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\tVnF3UUN3ME2xMlQxPjh|IN88US=> MofIV2FPT0WU
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPwTll6UUN3ME2xMlQ{QTl4IN88US=> MoG4V2FPT0WU
BT-549 M{X0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmweotKSzVyPUGuOVY6ODlizszN MUfTRW5ITVJ?
NKM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNkC1OVYh|ryP NWHtZm1jW0GQR1XS
SW780 NUPSWllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XlTWlEPTB;MT62OVE2QCEQvF2= MVPTRW5ITVJ?
NCI-H292 NF65enRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX6TWM2OD1zLk[2N|g{KM7:TR?= NH3mPXhUSU6JRWK=
HMV-II NHP2b3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXNTWM2OD1zLkewOFg5KM7:TR?= M{i3eXNCVkeHUh?=
ALL-PO MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHRVo5KSzVyPUGuPFAxOTVizszN NVXFXIhbW0GQR1XS
UACC-257 NH3keIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2d2lEPTB;MT64NlE3OyEQvF2= MVzTRW5ITVJ?
PA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zhTWlEPTB;MT64NlczPSEQvF2= NVfwUG12W0GQR1XS
HD-MY-Z NVnLc3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ZOGFKSzVyPUGuPFYzQDFizszN Mon3V2FPT0WU
HSC-4 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwOUO4N|kh|ryP Mn71V2FPT0WU
GCT NHvsSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwMEC5NVYh|ryP M3XESXNCVkeHUh?=
RT-112 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwMUO0NlQh|ryP NGjrU4FUSU6JRWK=
A172 M{TKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHYTWM2OD1{LkGzOlA3KM7:TR?= MlHwV2FPT0WU
HCE-T NF7WeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvNTWM2OD1{LkKwOVk5KM7:TR?= NXzU[YZTW0GQR1XS
YH-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfRWGFKSzVyPUKuNlE3PzFizszN MVLTRW5ITVJ?
DK-MG MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv6WW5KSzVyPUKuNlM5OzRizszN MVXTRW5ITVJ?
ACN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwMkO4O|Uh|ryP M3myNnNCVkeHUh?=
VA-ES-BJ MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwMkS5OVch|ryP NUPaepVXW0GQR1XS
L-363 M1\1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37uUGlEPTB;Mj6yPFA3OSEQvF2= NYrOfnZtW0GQR1XS
HuH-7 M{jjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLhTmpXUUN3ME2yMlQzOTZ3IN88US=> MoTuV2FPT0WU
A4-Fuk MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6wdW5sUUN3ME2yMlQ4OTZ6IN88US=> NWC2NVFuW0GQR1XS
T-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jxc2lEPTB;Mj60PFA{PyEQvF2= M1jtSHNCVkeHUh?=
GOTO NFnYWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjkTWM2OD1{LkWzNFE{KM7:TR?= MkS2V2FPT0WU
MV-4-11 M2rpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP6TWM2OD1{LkW5NVY6KM7:TR?= MlvmV2FPT0WU
DMS-114 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn71TWM2OD1{Lk[2N|Q2KM7:TR?= MnK0V2FPT0WU
MHH-NB-11 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwN{CyPVkh|ryP NHXQcnRUSU6JRWK=
CHP-212 NY\rPGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ztUWlEPTB;Mj64NlA6OSEQvF2= NIG0SFNUSU6JRWK=
DMS-273 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwOUCyNFch|ryP Mn\RV2FPT0WU
SF295 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fPWmlEPTB;Mz6wNlU6PyEQvF2= M4\KTXNCVkeHUh?=
NCI-H1563 NYjoNJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGwTWM2OD1|LkG1NFA2KM7:TR?= MVnTRW5ITVJ?
NCI-H446 M1K2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS1TWM2OD1|LkKyPFA2KM7:TR?= NXXzU2hMW0GQR1XS
HCC1806 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3STWM2OD1|LkK3OlU4KM7:TR?= M4Pue3NCVkeHUh?=
SF126 M{myfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7XTWM2OD1|LkOwNFE4KM7:TR?= NEf1O49USU6JRWK=
SW982 M{PNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLETWM2OD1|LkOzPFc2KM7:TR?= Ml;WV2FPT0WU
ES8 M{npXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\kcItKSzVyPUOuN|Q6QTlizszN MlKwV2FPT0WU
SCC-4 NVL5b45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwNUCzPVYh|ryP NHLoOI9USU6JRWK=
RPMI-8226 NXOxN|N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2yTWM2OD1|Lk[yOlE3KM7:TR?= NFLUb4dUSU6JRWK=
EW-11 NYTVV|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLxUIRKSzVyPUOuOlMxOjJizszN MUDTRW5ITVJ?
COR-L105 M3\SbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwNkOzN|Qh|ryP M4XNR3NCVkeHUh?=
ES1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHUTWM2OD1|LkizNFk1KM7:TR?= NEftdXRUSU6JRWK=
KMOE-2 NUi1VZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnaUYFKSzVyPUOuPVE5ODhizszN M33OVXNCVkeHUh?=
ABC-1 NF7LXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPvNnNKSzVyPUOuPVM6OTFizszN NV\Ld2ZTW0GQR1XS
NCI-H526 M1O3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vpe2lEPTB;Mz65PVEzPiEQvF2= MXfTRW5ITVJ?
HCC1395 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwOUm0PFQh|ryP NUHRUVlNW0GQR1XS
DU-145 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfENFYzUUN3ME20MlEzQDJ3IN88US=> NV7XZ5NIW0GQR1XS
JEG-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwMUW5NVYh|ryP MVvTRW5ITVJ?
HCC1187 M{nmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHjb2ZTUUN3ME20MlIyPTl5IN88US=> MYHTRW5ITVJ?
LC-2-ad NY\1WWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXETWM2OD12LkKyNVc4KM7:TR?= MYHTRW5ITVJ?
ONS-76 M3Lidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfoRWJKSzVyPUSuNlQyQTJizszN Mn3mV2FPT0WU
CAL-27 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\nTWM2OD12LkK0N|Q1KM7:TR?= NInGR3FUSU6JRWK=
8-MG-BA M1jT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5dmlEPTB;ND6yOlY2QCEQvF2= NVnhS2FlW0GQR1XS
HGC-27 NFvIXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLOTWM2OD12LkK5OlYh|ryP M4XJT3NCVkeHUh?=
Hs-578-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwM{G0Olgh|ryP M4PYPHNCVkeHUh?=
EW-1 M4PkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwNUOwNVQh|ryP M2q4OHNCVkeHUh?=
SW1573 M1\0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDpVpFMUUN3ME20MlU2OTZ|IN88US=> MnL3V2FPT0WU
SNU-423 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwNkC3PUDPxE1? NH3ZfnhUSU6JRWK=
HOS NHvqXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yemlEPTB;ND62PVc4KM7:TR?= MmTlV2FPT0WU
LB1047-RCC NWXhfWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjrR2JPUUN3ME20MlgyPDF6IN88US=> MYTTRW5ITVJ?
ChaGo-K-1 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO3eG4yUUN3ME20Mlg6ODR6IN88US=> NEH2VGhUSU6JRWK=
A3-KAW NHjWOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3ZTnNKSzVyPUSuPVc{PTJizszN MXzTRW5ITVJ?
CAS-1 M3\aSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvMTWM2OD12Lkm5PVA5KM7:TR?= MlvEV2FPT0WU
NBsusSR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwMEO1NVQh|ryP NHf0bYVUSU6JRWK=
KM12 NF23bZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS2VZhtUUN3ME21MlI6QDJ5IN88US=> NIPHd|hUSU6JRWK=
NCI-H1155 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTITWM2OD13LkO4NVg2KM7:TR?= MkHJV2FPT0WU
EFM-19 M1q2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\KTWM2OD13LkSxO|M4KM7:TR?= NHrXO4pUSU6JRWK=
D-392MG Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvDTWM2OD13LkW3PFQ6KM7:TR?= NFjEemxUSU6JRWK=
JVM-3 NVizSVFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC1VnhKSzVyPUWuO|I{OjVizszN NVfoflFPW0GQR1XS
EW-16 NHrzNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3jTWM2OD13Lke1OVg{KM7:TR?= MmPFV2FPT0WU
KARPAS-45 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjYTWM2OD13Lki0N|I2KM7:TR?= NWHvbnV6W0GQR1XS
NCI-H28 M3LacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M125TWlEPTB;NT64O|kyQCEQvF2= NHXtSpRUSU6JRWK=
COLO-829 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHGb|dKSzVyPUWuPVE2ODRizszN Mor1V2FPT0WU
KM-H2 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnHR29KSzVyPUWuPVI{QTVizszN MnvVV2FPT0WU
NCI-H82 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTVwOUK3O|Eh|ryP M{DQTHNCVkeHUh?=
OAW-42 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjaTWM2OD13Lkm4PFIyKM7:TR?= MXHTRW5ITVJ?
A704 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfaTWM2OD14LkGwOVc1KM7:TR?= NHnsTlRUSU6JRWK=
NCI-H1048 M1P3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZwMUC1PVkh|ryP NUXubHpuW0GQR1XS
LOXIMVI MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfReIpKSzVyPU[uNVEzPDhizszN NFTvWZhUSU6JRWK=
MKN45 MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLNdYlKSzVyPU[uNlYxOTZizszN NWjTWJNqW0GQR1XS
D-502MG NFTESJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPGTWpKSzVyPU[uNlg5PTdizszN MXLTRW5ITVJ?
HUTU-80 NV2xfIwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZwNEG2PFgh|ryP MXXTRW5ITVJ?
S-117 NE\4N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PY[GlEPTB;Nj61NFI3PyEQvF2= M1\IUXNCVkeHUh?=
HCC1569 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLmRZlKSzVyPU[uOVM4OzdizszN NG\POpRUSU6JRWK=
J-RT3-T3-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzrcW5KSzVyPU[uOVQ2PzJizszN MoDjV2FPT0WU
OC-314 NYPWNoZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PY[mlEPTB;Nj65NVE2QSEQvF2= MoKzV2FPT0WU
SNU-449 NVr6TnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJXok4UUN3ME23MlAyODd{IN88US=> NYPKeFIyW0GQR1XS
NCI-H720 NH;ERodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkO49vUUN3ME23MlE6OzR3IN88US=> M3LFV3NCVkeHUh?=
KP-N-YS MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT6NlNGUUN3ME23MlIxPzJizszN M1fofHNCVkeHUh?=
IGROV-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPSSFRKSzVyPUeuN|I{QDZizszN NYTUZ41UW0GQR1XS
SK-PN-DW M4XoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fxU2lEPTB;Nz60PFE2KM7:TR?= NYDue|hNW0GQR1XS
HCC1419 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdwNUOg{txO MXTTRW5ITVJ?
HAL-01 NYDXdlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwNkC2OFQh|ryP MojyV2FPT0WU
HCC2998 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTdwNkC3OFMh|ryP NUi0VWd5W0GQR1XS
SK-N-FI Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDTWM2OD15Lk[zNFM{KM7:TR?= M1PDUnNCVkeHUh?=
GI-ME-N Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\yTWM2OD15Lk[0PVM1KM7:TR?= MVHTRW5ITVJ?
SW1088 NXXhc2JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3eHlKSzVyPUeuOlU5OjZizszN NFvQVohUSU6JRWK=
IA-LM M4fpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTdwNki2NVMh|ryP NYTTbFRQW0GQR1XS
SK-NEP-1 NYPTeZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\sXFhCUUN3ME23MlY6PjFizszN NVT6OnVvW0GQR1XS
MDA-MB-415 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHySIJKSzVyPUeuPFkyQDZizszN MUfTRW5ITVJ?
COLO-800 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TFSWlEPTB;Nz65OFQ6OiEQvF2= Ml24V2FPT0WU
NCI-H2228 NFnuXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRThwMUW3PFMh|ryP MkGxV2FPT0WU
D-423MG NFLId4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z1TWlEPTB;OD6yNVczKM7:TR?= M3HXUXNCVkeHUh?=
TE-1 NGLLUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJfY1CUUN3ME24MlQ1OzF4IN88US=> NEnQTYlUSU6JRWK=
NOS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\kTWlEPTB;OD61NVU{PCEQvF2= MkDvV2FPT0WU
8505C NVLqPJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOemJKSzVyPUiuOlQ5OjRizszN M{fXZXNCVkeHUh?=
HEC-1 M4\wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Hb2lEPTB;OD63PFQ{QSEQvF2= MXLTRW5ITVJ?
TE-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXKTWM2OD16Lkm5OVUyKM7:TR?= MUDTRW5ITVJ?
CTB-1 M2f6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPiV4lKSzVyPUmuNFE1OzNizszN MorUV2FPT0WU
TGBC11TKB Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPvOYlKSzVyPUmuNFIzPDFizszN NH;Se|NUSU6JRWK=
NB17 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\UTWM2OD17LkG4PFch|ryP M2\FTnNCVkeHUh?=
Becker M{\kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u2VWlEPTB;OT60NVk1PCEQvF2= NGW2UZVUSU6JRWK=
SN12C MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGc2NKSzVyPUmuOFUzOzRizszN Mn\mV2FPT0WU
COLO-320-HSR M{\HRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnRZYhKSzVyPUmuOlAzOzdizszN NIf6dlRUSU6JRWK=
D-283MED NIL1eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTlwNkOwO|Ih|ryP NUjvUJJRW0GQR1XS
D-263MG NFXOd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTCXmFKSzVyPUmuPFM{QDRizszN MliyV2FPT0WU
MEL-JUSO MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTlwOUCxNlch|ryP Mm\4V2FPT0WU
T98G NF;rVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6zZY1KSzVyPUmuPVAzODNizszN MnrtV2FPT0WU
HLE MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\PXoRKSzVyPUmuPVA6ODlizszN MX\TRW5ITVJ?
Ca9-22 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLieY9pUUN3ME2xNE4xPjZ3IN88US=> NH7VPHBUSU6JRWK=
OS-RC-2 NFewe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLGTWM2OD1zMD6xNFQ2KM7:TR?= NHLmZmZUSU6JRWK=
T47D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFyLkG1OUDPxE1? MXzTRW5ITVJ?
GI-1 M3Hn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFyLkO1N|Mh|ryP NFW3blFUSU6JRWK=
NUGC-3 NYXUXWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQd|VKSzVyPUGwMlQ1ODJizszN MmDaV2FPT0WU
MDA-MB-361 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTlWZZKSzVyPUGwMlQ1OzJizszN MoK1V2FPT0WU
SCC-15 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETG[odKSzVyPUGwMlQ4OThizszN M2\rUHNCVkeHUh?=
KS-1 NYDDdW5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET0SodKSzVyPUGwMlY{ODFizszN M3r0PHNCVkeHUh?=
CAL-12T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFyLk[zOlEh|ryP Mor4V2FPT0WU
OVCAR-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK1TWM2OD1zMD63NFY5KM7:TR?= MV;TRW5ITVJ?
HuP-T4 M4DETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFzLkCzNlgh|ryP M1zZSHNCVkeHUh?=
NCI-H358 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGzTVNKSzVyPUGxMlI3PTdizszN MWDTRW5ITVJ?
HO-1-N-1 NEHhdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPm[WV{UUN3ME2xNU4{Ozl6IN88US=> NYrEPFFYW0GQR1XS
NH-12 M4q3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK5TWM2OD1zMT61N|c5KM7:TR?= MXTTRW5ITVJ?
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjKbWZGUUN3ME2xNU42QTh3IN88US=> NUj4R|U5W0GQR1XS
K-562 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjYbZRKSzVyPUGxMlczPDhizszN MXzTRW5ITVJ?
ES6 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTFb2ZKSzVyPUGxMlg2QDFizszN NIHQWohUSU6JRWK=
RO82-W-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHFXIlKSzVyPUGxMlkxPjRizszN MnTzV2FPT0WU
Ramos-2G6-4C10 NHTIdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTxTIdyUUN3ME2xNU46OzJizszN MkC4V2FPT0WU
23132-87 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfDVHlKSzVyPUGyMlA5OjFizszN M1jjRnNCVkeHUh?=
A549 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MleyTWM2OD1zMj6zNlg2KM7:TR?= NUXDWIxkW0GQR1XS
NCI-H23 NVTCbnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PqXGlEPTB;MUKuOVAzPiEQvF2= M1zFd3NCVkeHUh?=
H9 NUHKW25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;kfpBQUUN3ME2xNk42PTd5IN88US=> NWHsTnNnW0GQR1XS
LB771-HNC NHTlfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrDTWM2OD1zMj63OlUh|ryP M3TXbHNCVkeHUh?=
QIMR-WIL NVrJdox{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF{LkiyOVgh|ryP NEfiXHVUSU6JRWK=
HSC-3 NGXNbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDvblNKSzVyPUGyMlkzPzZizszN NInoTW5USU6JRWK=
PFSK-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXMTWM2OD1zMj65OVA4KM7:TR?= MX\TRW5ITVJ?
ETK-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTJTWM2OD1zMz6wO|c6KM7:TR?= M4fXTXNCVkeHUh?=
SW1710 NX3rRnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLITWM2OD1zMz6zOlQyKM7:TR?= MXLTRW5ITVJ?
COLO-684 M4e3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rFT2lEPTB;MUOuOFU1OSEQvF2= MWfTRW5ITVJ?
RPMI-7951 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfKXGJmUUN3ME2xN{42OTN4IN88US=> NWrwNlA5W0GQR1XS
A101D NH33d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fyOWlEPTB;MUOuOVM1QSEQvF2= NGPnUYhUSU6JRWK=
KE-37 NGXy[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|LkW4PFch|ryP NHfsfIFUSU6JRWK=
SiHa M{LuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF|LkizOFYh|ryP NH\FOpdUSU6JRWK=
NCI-H226 NFP6[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLJfFBKSzVyPUGzMlg5ODhizszN NX7RZVdDW0GQR1XS
DB Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\BTWM2OD1zMz65PVI5KM7:TR?= Mm\PV2FPT0WU
HT-1197 M37TXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2LkC4NFkh|ryP MkLNV2FPT0WU
SBC-5 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvP[ndtUUN3ME2xOE4yOzZ{IN88US=> MWnTRW5ITVJ?
VMRC-RCZ MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF2LkW3O|Qh|ryP NWjxNnV1W0GQR1XS
697 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfqTWM2OD1zND62Nlch|ryP NEDWRWJUSU6JRWK=
OMC-1 M2TYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;MRZExUUN3ME2xOE44QDh6IN88US=> MX\TRW5ITVJ?
SKG-IIIa MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWwWHhKSzVyPUG0MlgxODFizszN M2niZnNCVkeHUh?=
DOK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3CTWM2OD1zND65PVM{KM7:TR?= MlXZV2FPT0WU
NCI-H2029 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF3LkO2NFIh|ryP NYjVWoxZW0GQR1XS
NCI-H2009 M{TDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1zNT61NFk2KM7:TR?= NVTUZpV6W0GQR1XS
LK-2 M2DD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ZPWlEPTB;MUWuOlQ1QSEQvF2= MUXTRW5ITVJ?
NCI-H661 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\kV2lEPTB;MUWuPVA4PSEQvF2= MkXxV2FPT0WU
GT3TKB NWfvV4lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD1zNj6wOlc3KM7:TR?= NHHBfopUSU6JRWK=
GP5d M2TvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTW[245UUN3ME2xOk4{PDJizszN MV3TRW5ITVJ?
SK-MEL-2 NGjzPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNeGlEPTB;MU[uOFQ5PSEQvF2= M2rOUHNCVkeHUh?=
SK-UT-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF4LkW2OUDPxE1? M2C3d3NCVkeHUh?=
NB7 NXXa[HZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljRTWM2OD1zNj62PVcyKM7:TR?= M37Cd3NCVkeHUh?=
NCI-H460 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TTWM2OD1zNj63N|I3KM7:TR?= NUm0dVk2W0GQR1XS
8305C Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF4Lke4O|ch|ryP M4r0d3NCVkeHUh?=
CaR-1 NHPXUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF4LkixNVEh|ryP Mn\GV2FPT0WU
D-247MG MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXBTWM2OD1zNj64OlI2KM7:TR?= NYTsemVRW0GQR1XS
LoVo MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rCfmlEPTB;MU[uPVQ5QCEQvF2= NE\yS|NUSU6JRWK=
NCI-H2405 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvaZ5pKSzVyPUG3MlE6ODhizszN MX3TRW5ITVJ?
AU565 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHwbFJ1UUN3ME2xO{4zOjVizszN MUHTRW5ITVJ?
OCI-AML2 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP1fnVjUUN3ME2xO{42OzF5IN88US=> M2fpTXNCVkeHUh?=
22RV1 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H1OGlEPTB;MUeuOVg5PCEQvF2= NUDDW5hNW0GQR1XS
HT-144 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF5Lk[1PVgh|ryP NHLsNVZUSU6JRWK=
HuO9 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF5LkewN|Eh|ryP M3vyOXNCVkeHUh?=
Daoy Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvleWpKSzVyPUG3MlcyQDRizszN MY\TRW5ITVJ?
SJRH30 NWH6WVJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm1dnBkUUN3ME2xO{45PDh7IN88US=> MVjTRW5ITVJ?
CHL-1 NGXJTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvsV3hKSzVyPUG3MlkzPDlizszN NHfoeFNUSU6JRWK=
J82 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\QTWM2OD1zNz65OlM2KM7:TR?= MVfTRW5ITVJ?
COR-L23 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rm[2lEPTB;MUiuNFAyOSEQvF2= M1fGTXNCVkeHUh?=
SNU-C2B MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5TWM2OD1zOD6yNlc3KM7:TR?= NF\3XoJUSU6JRWK=
NCI-H1770 NWDyWmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLq[ohKSzVyPUG4MlQ3OTVizszN NGPjSmNUSU6JRWK=
MHH-PREB-1 NVvZUZBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF6LkW2PVch|ryP M2G5THNCVkeHUh?=
ES3 M4\nRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF6LkW4PFMh|ryP MojOV2FPT0WU
MDA-MB-231 NV7ORpBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV24b2hMUUN3ME2xPE43PTB{IN88US=> NXnoe2ZSW0GQR1XS
MN-60 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHU[oRKSzVyPUG5MlA2QTJizszN MkC4V2FPT0WU
EPLC-272H NF[xRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXUTWM2OD1zOT6zO|A5KM7:TR?= NHfVT4NUSU6JRWK=
SW948 M37hSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF7LkO5N|Qh|ryP NUH2TJJMW0GQR1XS
MOLT-13 NIDncIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LXWGlEPTB;MUmuOFU1PiEQvF2= NX;TXW1YW0GQR1XS
HL-60 M4XG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJyLkKxOFEh|ryP Ml[2V2FPT0WU
CP50-MEL-B MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLTTWM2OD1{MD60O|Q5KM7:TR?= MoizV2FPT0WU
NTERA-S-cl-D1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS1N49KSzVyPUKwMlQ6PzhizszN M{LadHNCVkeHUh?=
KINGS-1 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5TWM2OD1{MD63PVY4KM7:TR?= Mny4V2FPT0WU
DOHH-2 NH7xZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6wXpBKSzVyPUKwMlkxPiEQvF2= Mlv0V2FPT0WU
BB65-RCC NUf1SXpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJyLkmyPFUh|ryP NXjtcFF2W0GQR1XS
NB12 NYfOZoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f0W2lEPTB;MkGuNFM6PCEQvF2= M{fGZnNCVkeHUh?=
KY821 NFrtR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfJTWM2OD1{MT61PFIh|ryP MVTTRW5ITVJ?
PSN1 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJzLk[0OVMh|ryP M{nzdXNCVkeHUh?=
EGI-1 M4faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTLTWM2OD1{MT63OFU1KM7:TR?= NIjHeXFUSU6JRWK=
CTV-1 M162NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\2VYpKSzVyPUKyMlMxOzFizszN M3;Jb3NCVkeHUh?=
TI-73 NXjQfIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3[2lEPTB;MkKuN|Q6QCEQvF2= NFLhU|FUSU6JRWK=
LCLC-103H NVvuXnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHzTWM2OD1{Mj60O|UzKM7:TR?= Mlf2V2FPT0WU
D-542MG MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK1TWM2OD1{Mj61OVU5KM7:TR?= NE\vblhUSU6JRWK=
ATN-1 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSydJZlUUN3ME2yNk43PDN7IN88US=> MlnpV2FPT0WU
SK-MEL-1 NUOxbmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ{LkizOlgh|ryP NH;3XGVUSU6JRWK=
HDLM-2 NGTibGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ|LkG0O|gh|ryP M{PkcXNCVkeHUh?=
UM-UC-3 M{DFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkG5OFQh|ryP MWfTRW5ITVJ?
NCI-H1573 NHrifZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ|LkS2PFEh|ryP NFjxN3NUSU6JRWK=
NCI-H520 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XiRWlEPTB;MkOuOFk1QCEQvF2= NHHJeFBUSU6JRWK=
ESS-1 NHTBNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3UmlEPTB;MkOuPFA2QSEQvF2= M3jaN3NCVkeHUh?=
COR-L88 M2XGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1{Mz65OFc2KM7:TR?= MkDKV2FPT0WU
TGBC24TKB NWnYbop4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5d|BKSzVyPUK0MlA{OTJizszN NYnUUGVJW0GQR1XS
HCC1937 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf1TWM2OD1{ND6xJO69VQ>? NYPTb5FsW0GQR1XS
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3np[GlEPTB;MkSuNVQzKM7:TR?= NWPVRZF7W0GQR1XS
HCC38 M2S2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFriVm1KSzVyPUK0MlI{QTRizszN NV;jeHlkW0GQR1XS
RPMI-2650 NGDxeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTvTWM2OD1{ND62NVYzKM7:TR?= MWHTRW5ITVJ?
P12-ICHIKAWA NVHlOZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ2Lk[yOVgh|ryP NGHhUmxUSU6JRWK=
YAPC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4fJNKSzVyPUK0MlgzOTRizszN NHzsXmJUSU6JRWK=
NB13 NICyTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP4TWM2OD1{NT6yOlEyKM7:TR?= MUnTRW5ITVJ?
SK-N-AS Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPhbJdKSzVyPUK1Mlg2QDRizszN MV;TRW5ITVJ?
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrWTWM2OD1{Nj6wOFkh|ryP NHftTGZUSU6JRWK=
LS-411N NWmzTnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ4LkKwN|gh|ryP M3vGXHNCVkeHUh?=
NCI-H810 NGfLO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPOTWM2OD1{Nj6zNVEzKM7:TR?= MXrTRW5ITVJ?
NCI-SNU-1 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTlTWM2OD1{Nj61OFU1KM7:TR?= NX7YdZh2W0GQR1XS
HH MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XweGlEPTB;Mk[uOVUzQSEQvF2= M17CU3NCVkeHUh?=
U-2-OS M2D0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ4LkezPFIh|ryP MXjTRW5ITVJ?
SF539 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hye2lEPTB;Mk[uPFAyQCEQvF2= MnXjV2FPT0WU
NCI-H2052 NYO2enJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ5LkC4OkDPxE1? M2D3eXNCVkeHUh?=
A673 M3LxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LWfmlEPTB;MkeuNlExOiEQvF2= NHrndVNUSU6JRWK=
WM-115 NW\wfIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvT2lEPTB;MkeuO|c3PyEQvF2= NHziWnNUSU6JRWK=
SW48 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fxZ2lEPTB;MkeuPFAxPSEQvF2= M1z3UnNCVkeHUh?=
NOMO-1 NFzpW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm3S2xnUUN3ME2yO{45PTN{IN88US=> NH3NWo9USU6JRWK=
PC-3 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;mWGlEPTB;MkeuPFk1OSEQvF2= MoTvV2FPT0WU
UMC-11 NWjUT4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTEPYJKSzVyPUK3Mlk{PDNizszN NITyOXlUSU6JRWK=
U-118-MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ6LkCxNlMh|ryP Mly2V2FPT0WU
NCI-H2452 NETufZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ6LkC4NlIh|ryP NIL5c41USU6JRWK=
CAMA-1 NWPUbWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjNOYdKSzVyPUK4Mlg2PjRizszN MULTRW5ITVJ?
MC-IXC M4mzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3[YtKSzVyPUK5MlI{PjZizszN M3Hu[HNCVkeHUh?=
ES4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ7LkOxO|Ih|ryP M{TFRnNCVkeHUh?=
BHT-101 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJ7LkOyNUDPxE1? NG\nfmJUSU6JRWK=
KP-4 M2fMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD6TWM2OD1{OT61NVYh|ryP NWThbpU2W0GQR1XS
CAL-54 NX3JZnZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ7LkW0OFUh|ryP NVrtXlBMW0GQR1XS
5637 NEXod2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ7Lk[0NlEh|ryP NHzZe3RUSU6JRWK=
MOLT-16 NGfVOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzXOo1KSzVyPUK5MlczPjlizszN NYLIRYdUW0GQR1XS
Ca-Ski NXHN[ohpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\M[3FKSzVyPUK5Mlk1PiEQvF2= NXHCcHRTW0GQR1XS
AsPC-1 Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\BWJBKSzVyPUOwMlAzOTJizszN NGPiPFZUSU6JRWK=
MSTO-211H M3K2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNyLkG1JO69VQ>? MmPSV2FPT0WU
L-428 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNyLkSwOUDPxE1? MUTTRW5ITVJ?
SW1463 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q2WmlEPTB;M{CuOVM5OyEQvF2= M3jZWHNCVkeHUh?=
NCI-H1648 NYXZTZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnaeGI2UUN3ME2zNE42PTd2IN88US=> MWXTRW5ITVJ?
CAKI-1 NX3YW3RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTOTJpZUUN3ME2zNE44PzB{IN88US=> M1POVXNCVkeHUh?=
YKG-1 NFrjRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\3VWlEPTB;M{GuNFI3OyEQvF2= M1:5bnNCVkeHUh?=
A2058 M1f2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHLNHRKSzVyPUOxMlEyPjRizszN MWfTRW5ITVJ?
A375 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNzLkG2PVYh|ryP M4DYNXNCVkeHUh?=
SNB75 NYjrWmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITZSGhKSzVyPUOxMlI1OzVizszN NGXHUppUSU6JRWK=
SK-HEP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1|MT60NlcyKM7:TR?= MUTTRW5ITVJ?
ME-180 M3;oVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLTTWM2OD1|MT62OVQzKM7:TR?= MlnIV2FPT0WU
NCI-H209 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNzLkiyOFch|ryP NFTsZ4xUSU6JRWK=
HC-1 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7VTWM2OD1|Mj6xOFQ3KM7:TR?= MWHTRW5ITVJ?
LB373-MEL-D NWLVemtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f6bWlEPTB;M{KuNVk4OSEQvF2= NWXJSJlmW0GQR1XS
SNU-387 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LBWWlEPTB;M{KuN|E6OSEQvF2= NYnmRVNMW0GQR1XS
C32 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHxTJVKSzVyPUOyMlM{PTNizszN NIXwOYpUSU6JRWK=
EW-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN{Lkm0NFgh|ryP Mn3PV2FPT0WU
BFTC-905 M1vQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPXTWM2OD1|Mz61NVM3KM7:TR?= MlvqV2FPT0WU
NCI-H1299 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7kN2pKSzVyPUOzMlU3OjFizszN MWLTRW5ITVJ?
LU-135 NWLtdmljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTvTWM2OD1|Mz64NFEh|ryP MVnTRW5ITVJ?
NCI-H2122 M{jG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TXPGlEPTB;M{OuPVk3PiEQvF2= M{fISHNCVkeHUh?=
SK-LMS-1 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN2LkSxNFch|ryP M{HKTnNCVkeHUh?=
LNCaP-Clone-FGC M4fvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\PenhKSzVyPUO0Mlg2OTVizszN MmfJV2FPT0WU
NCI-H1092 M3X3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN3LkK3OFch|ryP MUDTRW5ITVJ?
MS-1 M4\Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxWWlEPTB;M{WuN|A{QCEQvF2= M3jve3NCVkeHUh?=
KYSE-510 NE\3PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN3LkWwOFIh|ryP NWqzToRFW0GQR1XS
NCI-H1793 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ryNWlEPTB;M{WuOlU1PSEQvF2= MWTTRW5ITVJ?
MIA-PaCa-2 NH3y[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyRZg1UUN3ME2zOk4xPDl4IN88US=> MWPTRW5ITVJ?
EW-22 NHLHeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6fpcxUUN3ME2zOk41ODd{IN88US=> MULTRW5ITVJ?
IGR-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nYfmlEPTB;M{[uPFE5PCEQvF2= NHH2V4RUSU6JRWK=
HT-1080 NIrh[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\IZpdmUUN3ME2zO{4yOjVizszN NETZeG5USU6JRWK=
M14 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIraTHZKSzVyPUO3MlE3PDJizszN NXqzWJI{W0GQR1XS
786-0 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S0UGlEPTB;M{euNlc6PCEQvF2= MWHTRW5ITVJ?
MZ2-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTN5LkS1NFEh|ryP M2Pnc3NCVkeHUh?=
NCI-H510A NGrIVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrxTWM2OD1|Nz65OFEzKM7:TR?= NFGzVHZUSU6JRWK=
LAN-6 M4[zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT3TWM2OD1|Nz65OVgzKM7:TR?= MkizV2FPT0WU
SW620 NG\kWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztfYdjUUN3ME2zPE41QTd2IN88US=> MVfTRW5ITVJ?
LB2241-RCC Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfQSHpKSzVyPUO5MlgzODVizszN NUfLOJJoW0GQR1XS
Detroit562 NWXBT2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknwTWM2OD12MD6xNlY5KM7:TR?= NGnXOIRUSU6JRWK=
HN M2foZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xblRTUUN3ME20NE4yPzh{IN88US=> MlH2V2FPT0WU
HCT-15 NIXRU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRVmlEPTB;NECuOVkxPyEQvF2= M4fBcHNCVkeHUh?=
C2BBe1 NGLNcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTJTWM2OD12MD65NVU4KM7:TR?= NYjINmV4W0GQR1XS
A498 M2DscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRzLkOwNVUh|ryP NYm5cW5{W0GQR1XS
SK-MEL-24 NVfTfHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRzLkS3NlUh|ryP NXPH[|VZW0GQR1XS
OVCAR-5 NIjiS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnQTWM2OD12MT63O|Y4KM7:TR?= NYjFWHJtW0GQR1XS
NCI-H1792 NFfoZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT5TWM2OD12MT65PFIyKM7:TR?= NW\YXnc{W0GQR1XS
KOSC-2 NX3oeHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR{LkK2PVkh|ryP NXTKVm5DW0GQR1XS
Mo-T Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTR{Lki5OVgh|ryP MWDTRW5ITVJ?
CFPAC-1 NW\wVpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR|LkS5OFQh|ryP NIjnfGtUSU6JRWK=
CAL-51 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR|LkW2NFUh|ryP NX7DR2t3W0GQR1XS
RH-18 NWPsTmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzDfm1WUUN3ME20N{45ODVizszN M2LGWnNCVkeHUh?=
EC-GI-10 M2rm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz3dmVKSzVyPUSzMlg{PDdizszN M{m5e3NCVkeHUh?=
HSC-2 NGHjOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR2LkCwPUDPxE1? Mn3xV2FPT0WU
ML-2 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHzcItGUUN3ME20OU4zPjJzIN88US=> MlnIV2FPT0WU
KNS-81-FD NYn2[5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HSbGlEPTB;NEWuO|M3PSEQvF2= MX3TRW5ITVJ?
NB6 NX3DcnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3hSG93UUN3ME20Ok4yOTFizszN NEnNfIlUSU6JRWK=
MCF7 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmxTWM2OD12Nj61OVM{KM7:TR?= MlfUV2FPT0WU
P30-OHK Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DKVGlEPTB;NE[uPFEyPyEQvF2= MVPTRW5ITVJ?
BPH-1 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTR4Lkm4NFUh|ryP NVy1R4dDW0GQR1XS
U251 NIXSenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjUc|A3UUN3ME20Ok46QTRizszN M3HPVXNCVkeHUh?=
MKN1 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR5LkWxN|ch|ryP MV\TRW5ITVJ?
A431 NHS2RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[1TWM2OD12Nz64N|M5KM7:TR?= M1vYN3NCVkeHUh?=
C8166 M3rlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3od2lKSzVyPUS5MlIxOzlizszN MlHlV2FPT0WU
HEL NGS4[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTYTWM2OD12OT60NFY1KM7:TR?= MXnTRW5ITVJ?
RMG-I NVO1NGtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXlbZZKSzVyPUS5MlQ1PDRizszN NEXwcnFUSU6JRWK=
CAL-72 M{XXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR7Lk[wO|Uh|ryP NGLtU2pUSU6JRWK=
SW962 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELzdXFKSzVyPUS5Mlk{OzJizszN MX;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

- Collapse

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

- Collapse
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04033991 Not yet recruiting Drug: Sunitinib|Drug: Axitinib Carcinoma|Renal Cell Pfizer September 2019 --
NCT03472560 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Non-Small Cell Lung Cancer|Urothelial Cancer Pfizer May 2 2018 Phase 2
NCT03592199 Active not recruiting Drug: Sunitinib Clear Cell Renal Cell Carcinoma Instituto do Cancer do Estado de São Paulo|Pfizer December 11 2017 Phase 2
NCT03289533 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Carcinoma Hepatocellular Pfizer September 8 2017 Phase 1
NCT00460603 Completed Drug: bevacizumab|Drug: AG-013726|Drug: AG-013736 (axitinib) Colorectal Neoplasms Pfizer January 2006 Phase 1|Phase 2
NCT00219557 Completed Drug: Gemcitabine|Drug: AG-013736 Pancreatic Neoplasms Pfizer July 5 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID